Increasing the public activity cliff knowledge base with new categories of activity cliffs

Huabin Hu1 & Jürgen Bajorath*,1
1Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology & Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Endenicher Allee 19c, Bonn D-53113, Germany
*Author for correspondence: Tel.: +49 228 7369 100; Fax: +49 228 7369 101; bajorath@bit.uni-bonn.de

Aim: Extending the public knowledge base of activity cliffs (ACs) with new categories of ACs having special structural characteristics. Methodology: Dual-site ACs, isomer ACs and ACs with privileged substructures are described and their systematic identification is detailed. Exemplary results & data: More than 7400 new ACs belonging to different categories with activity against more than 200 targets were identified and are made publicly available. Limitations & next steps: For dual-site ACs, limited numbers of isomers are available as structural analogs for rationalizing contributions to AC formation. The search for such analogs will continue. In addition, the target distribution of ACs containing privileged substructures will be further analyzed.

Lay abstract: Activity cliffs (ACs) are formed by small molecules that have very similar structures, are active against the same biological target, but have a large difference in potency against their target. Accordingly, ACs are of interest in medicinal chemistry because they reveal small structural changes that greatly influence the potency of active compounds. This information can be used for compound optimization. Computational methods are applied to search for ACs in large compound databases. Here, we further extend the public AC knowledge base with new categories of ACs having special structural characteristics.

Graphical abstract: Shown are an exemplary dual-site activity cliff (AC) (top), isomer AC (middle) and an AC containing a privileged substructure (bottom). Structural differences between AC compounds are highlighted in blue and the privileged substructure is colored pink. Compound targets and potency (pKi) values are reported.
Activity cliffs (ACs) are defined as pairs or groups of structurally similar (analogous) compounds that are active against the same target but have a large difference in potency [1–4]. ACs have also been studied on the basis of compounds, which are highly potent against a given target and structural analogs that are confirmed inactive against this target [4]. Furthermore, ACs have been investigated from a variety of research perspectives including the consideration of different AC concepts, different types of data analysis and AC predictions [1–9]. In medicinal chemistry, ACs are of particular interest because they capture small chemical modifications of active compounds that substantially contribute to, or determine, structure–activity relationships (SARs) [2,3].

For formally defining ACs, molecular similarity and potency difference criteria must be specified [2–4]. Similarity can be calculated on the basis of chemical descriptors and numerical similarity metrics (descriptor-based/numerical similarity) or on the basis of substructure relationships (substructure-based similarity) [3,4]. Substructure-based similarity measures include shared scaffolds, the formation of matched molecular pairs (MMPs) or membership in the same analog series (AS) [4,10,11]. Compounds forming MMP-based ACs are confined to chemical changes at a single substitution site [10,12], whereas AS-based ACs may contain single or multiple substitution sites [11,13].

Furthermore, for defining ACs, constant potency difference thresholds can be applied across different compound activity classes (e.g., at least 100-fold potency difference) [2,3]. Alternatively, activity class-dependent potency difference thresholds can be determined on the basis of statistically significant potency differences, with respect to intra-class potency value distributions [14,15]. In either case, the use of assay-independent equilibrium constants (Ki values) as potency measurements is generally preferred over assay-dependent measurements such as IC50 values. The use of Ki values makes it possible to compare ACs for a given target and across different targets in a meaningful way.

Considering the evolution of the AC concept in medicinal chemistry [4], we have defined three generations of ACs [4,16], depending on the structural similarity and potency difference criteria that are applied:

**First generation ACs**
- Similarity criterion: numerical or substructure-based similarity.
- Potency difference criterion: constant potency difference threshold across all activity classes.

**Second generation ACs**
- Similarity criterion: MMP formation (analog pairs with single substitution site).
- Potency difference criterion: variable activity class-dependent potency difference thresholds.

**Third generation ACs**
- Similarity criterion: structural analogs originating from the same AS (with single or multiple substitution sites).
- Potency difference criterion: variable activity class-dependent potency difference thresholds.

Previously, we have generated a large collection of second generation ACs [15,17] and made it publicly available as an open access deposition [17,18]. For nearly 100 different activity classes, each representing a unique target protein, more than 20,000 activity class-dependent ACs were identified, also taking structural analogs of potent compounds into account that were confirmed inactive against the same target [15,17]. Compound activity data were extracted from medicinal chemistry sources (ChEMBL database) [19] and high-throughput screens (PubChem Bioassays) [20].

Herein, we further increase the public AC knowledge base through addition of three recently introduced categories of ACs including dual-site ACs (ds-ACs) [13], isomer ACs (iso-ACs) [21] and ACs containing ‘privileged substructures’ (PS-ACs) [22]. These AC categories are detailed in the methodology section and an in-depth analysis of each category is reported in its original publication.

The PS concept was originally introduced in medicinal chemistry by Evans *et al.* [23] and has become increasingly popular over time [24,25]. PSs are frequently found in compounds with preferential activity against specific target families. They usually are not selective for a particular target but display a tendency of preferential binding to
Figure 1. Privileged substructures. Shown are the structures of 24 privileged substructures found in at least 100 unique bioactive compounds.

an individual target family over others. Accordingly, PSs are often considered as family-directed core structures in medicinal chemistry [23–25]. Studying PS-ACs is attractive because these ACs reveal different levels of SAR information associated with individual PSs, as described in detail [22].

In the following, we report a systematic search for ds-ACs, iso-ACs and PS-ACs, resulting in a new collection of ACs that further extends our knowledge base of ACs and is made available as an open access deposition. Importantly, ds-ACs, iso-ACs and PS-ACs were originally introduced in independent studies. Herein, we report a new unified search strategy that has made it possible to identify these ACs in bioactive compounds in concert applying consistent criteria, determine the overlap between different AC categories and study ACs belonging to these categories. This strategy is related to, yet distinct from the one applied in the original assessment of PS-ACs, which were most recently introduced [22], and has yielded the first public collection of PS-ACs. All new ACs identified in our systematic analysis are made freely available as a part of this study, providing a wealth of examples for follow-up investigations.

Methodology

Compound activity data

Bioactive compounds were extracted from the latest version of the ChEMBL [19] database (release 25). For selection of high-confidence activity data, rigorous criteria were applied. Only compounds forming direct interactions with human targets (i.e., assay relationship type ‘D’) at the highest assay confidence level (i.e., assay confidence score 9) were selected. Furthermore, only equilibrium constants (i.e., Ki values) with specified numerical values (‘=’ relationship) were accepted as potency measurements for given targets.

Privileged substructures

PSs were defined according to Welsch et al. [25]. A systematic search was carried out for PSs that were contained in 100 or more unique ChEMBL compounds. Figure 1 shows 24 PSs that were identified and further considered for AC analysis.

Compound fragmentation

To ensure consistent generation of ACs belonging to different categories, a recently introduced compound frag-
Figure 2. Exemplary activity cliffs belonging to different categories. From the top to the bottom, an exemplary ds-AC, iso-AC and PS-AC are shown. For each AC, the target and compound potency (pKi) values are reported. Structural modifications and the PS are colored blue and pink, respectively.

AC: Activity cliff; ds-AC: Dual-site activity cliff; iso-AC: Isomer activity cliff; PS: Privileged substructure.

A computation scheme was applied [22]. Using a decomposition algorithm for MMP generation [10], exocyclic single bonds in compounds were systematically fragmented, yielding two fragments per step. During the fragmentation process, the following size restrictions were applied to obtain a core and substituent fragment [12]. The number of nonhydrogen atoms of the core fragment was required to be at least twice as large as the number of nonhydrogen atoms comprising the substituent fragment. In addition, the size of the substituent was restricted to at most 13 nonhydrogen atoms. Furthermore, the substituent in the core fragment was replaced by a hydrogen atom (R → H). The calculations were carried out using in-house scripts with the aid of the OpenEye chemistry toolkit (NM, USA) (version 1.7.7) [26].

Analog pairs & activity cliffs
Following fragmentation, compounds having the same activity and sharing the same core were organized into individual sets of analogs. Then, analog pairs (APs) differing at two substitution sites were systematically enumerated and categorized as follows:

- Structural isomers: the same substituent occurred at two different sites (core positions).
Figure 3. Unified search strategy for the identification of different activity cliffs. The identification of ds-ACs, iso-ACs and PS-ACs is summarized. Numbers of compounds, targets and ACs are given at each stage.

AC: Activity cliff; CPD: Compound; ds-AC: Dual-site activity cliff; ds-AP: Dual-site analog pair; iso-AC: Isomer activity cliff; PS: Privileged substructure; PS-AC: Privileged substructure-containing activity cliff.

- Dual-site analogs: two different substituents occurred at different sites. The size difference between these exchanged substituents was restricted to at most eight non-hydrogen atoms.

For each AP, it was determined whether the participating compounds had an at least 100-fold difference in potency, which qualified the pair as an iso-AC or ds-AC. We note that iso-ACs are confined to structural isomers and hence distinct from chirality or chiral cliffs \(^{(4,9)}\) where cliff compounds are distinguished by different chirality at a given stereocenter. Furthermore, for each AC, it was determined if it contained a PS. ACs with PSs were also classified as PS-ACs. Figure 2 shows exemplary ACs belonging to different categories. By definition, iso-ACs represent a special case of ds-ACs.

Detection of isomers of dual-site activity cliff compounds
For ds-AC compounds, a further systematic search for structural isomers (from the same activity class) with the same substituent at the other substitution site was carried out. If such isomers were identified, it was possible
to generate an extended data structure for a ds-AC, revealing the contributions of substituent positions to AC formation, as further discussed below.

**Exemplary results & data**

**Unified search strategy for activity cliffs belonging to different categories**

Originally, ds-ACs, iso-ACs and PS-ACs were separately studied. Here, we have implemented a unified search strategy to identify ACs belonging to these categories in parallel and determine their overlap. The search strategy is summarized in Figure 3. After compound fragmentation, a total of 112,537 qualifying APs were identified that yielded a total of 7465 ACs, which were assigned to different categories, as further detailed below.

**Extended dual-site activity cliff data structure**

For SAR exploration, ds-ACs can be extended to generate a data structure comprising four analogs, as illustrated in Figure 4. This data structure makes it possible to examine the contributions of substituent positions to ds-AC formation and is thus rich in SAR information [13]. Its generation requires the identification of isomers of ds-AC compounds with inversely repositioned substituents, as shown in Figure 4. A systematic search for such isomers revealed that 396 ds-ACs could be fully extended with two qualifying isomers. In addition, for 2320 other ds-ACs,
only one isomer was identified. Among analogs from different series, structural isomers are statistically underrepresented when compared with analogs carrying different substituents. A possible reason might be that medicinal chemists, from an SAR perspective, typically prefer introducing different substituents at a given site, rather than synthesizing analogs with a 'moving' substituent (structural isomers). Regardless, the extended data structure based upon ds-ACs offers additional opportunities for SAR analysis and illustrates the utility of this AC category.

Data
Our systematic search identified a total of 3696 ACs without PSs that were formed by 2757 unique compounds with activity against 191 targets. These ACs included 3401 ds- and 295 iso-ACs. Thus, only a limited number of iso-ACs were available. In addition, the search identified 3769 PS-ACs formed by 2559 unique compounds with activity against 131 targets. These PS-ACs included 3544 ds- and 225 iso-ACs. ACs with and without PSs shared 84 targets.

Our analysis revealed that approximately half of the newly identified ACs contained one of 24 predefined PSs that were detected in at least 100 unique bioactive compounds. The high frequency with which a predefined set of PSs occurred in ds- and iso-ACs, thus combining different AC categories, indicated that PSs yielded SAR-informative compounds with potential for further optimization. Hence, on the basis of AC analysis, these PSs deserve further consideration in medicinal chemistry. The PS-ACs provided as a part of our study should aid in further exploring these PSs.

Data deposition
All ACs identified herein are provided in a text file. For each AC, category membership(s) are specified. For AC compounds, the ChEMBL ID, canonical SMILES representation and potency value are reported. For PS-ACs identified herein (forming a subset of iso-ACs and ds-ACs), the SMILES string of the PS is also provided. The data are made freely available as a deposition on the ZENODO open access platform [27].

Limitations & next steps
The extended ds-AC data structure enables the analysis of substitution site-specific contributions to AC formation. However, among structural analogs, structural isomers are under-represented and only limited numbers of isomers are currently available for ds-AC analysis. This is essentially the only data-dependent limitation associated with exploring the new AC categories introduced here. Hence, the search for isomers as structural analogs for ds-AC analysis will continue. Furthermore, the large number of PS-ACs we identified makes it possible to investigate the target distribution and SAR information content of PS-containing compounds and their analogs in greater detail. For this purpose, PS-ACs provide immediate focal points.
Author contributions
J Bajorath and H Hu conceived the study; H Hu carried out the analysis; H Hu and J Bajorath analyzed the results, J Bajorath and H Hu prepared the manuscript.

Acknowledgments
H Hu is supported by the China Scholarship Council (CSC).

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access
The work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1. Maggiora GM. On outliers and activity cliffs – why QSAR often disappoints. J. Chem. Inf. Model 46(4), 1535–1535 (2006).
   •• First explicit discussion of activity cliffs (ACs) in the chemical literature.
2. Stumpfe D, Bajorath J. Exploring activity cliffs in medicinal chemistry. J. Med. Chem. 55(7), 2932–2942 (2012).
   • First review of the AC concept in medicinal chemistry.
3. Stumpfe D, Hu Y, Dimova D, Bajorath J. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. J. Med. Chem. 57(1), 18–28 (2014).
4. Stumpfe D, Hu H, Bajorath J. Evolving concept of activity cliffs. ACS Omega 4(11), 14360–14368 (2019).
   • Most recent review of AC research and extension of the AC concept.
5. Cruz-Monteagudo M, Medina-Franco JL, Pérez-Castillo Y, Nicolotti O, Cordeiro MNDS, Borges F. Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde? Drug Discov. Today 19(8), 1069–1080 (2014).
6. Medina-Franco JL. Activity cliffs: facts or artifacts? Chem. Biol. Drug. Des. 81(5), 553–556 (2013).
7. Medina-Franco JL. Scanning structure–activity relationships with structure–activity similarity and related maps: from consensus activity cliffs to selectivity switches. J. Chem. Inf. Model. 52(10), 2485–2493 (2012).
8. Pérez-Benito L, Casajuana-Martín N, Jiménez-Rosés M, van Vlijmen H, Tresadern G. Predicting activity cliffs with free-energy perturbation. J. Chem. Theory Comput. 15(3), 1884–1895 (2019).
9. Schneider N, Lewis RA, Fechner N, Ertl P. Chiral cliffs: investigating the influence of chirality on binding affinity. ChemMedChem 13(13), 1315–1324 (2018).
10. Hussain J, Rea C. Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets. J. Chem. Inf. Model 50(3), 339–348 (2010).
11. Naveja JJ, Vogt M, Stumpfe D, Medina-Franco JL, Bajorath J. Systematic extraction of analogue series from large compound collections using a new computational compound–core relationship method. ACS Omega 4(1), 1027–1032 (2019).
12. Hu X, Hu Y, Vogt M, Stumpfe D, Bajorath J. MMP-cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs. J. Chem. Inf. Model 52(5), 1138–1145 (2012).
13. Stumpfe D, Hu H, Bajorath J. Introducing a new category of activity cliffs with chemical modifications at multiple sites and rationalizing contributions of individual substitutions. Bioorg. Med. Chem. 27(16), 3605–3612 (2019).
14. Hu H, Stumpfe D, Bajorath J. Rationalizing the formation of activity cliffs in different compound data sets. ACS Omega 3(7), 7736–7744 (2018).
15. Hu H, Stumpfe D, Bajorath J. Second-generation activity cliffs identified on the basis of target set-dependent potency difference criteria. Future Med. Chem. 11(5), 579–594 (2019).
   •• Introduction of ACs with variable potency difference thresholds.
16. Stumpfe D, Hu H, Bajorath J. Computational method for the identification of third generation activity cliffs. MethodsX 7, 100793 (2020).
17. Hu H, Stumpfe D, Bajorath J. Systematic identification of target set-dependent activity cliffs. Future Sci. OA 5(2), FSO363 (2019).
18. Hu H, Stumpfe D, Bajorath J. Target set-dependent activity cliffs (2018). https://doi.org/10.5281/zenodo.1436584
New categories of activity cliffs Data Note

19. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res.* 40(D1), D1100–D1107 (2012).

20. Wang Y, Bryant SH, Cheng T et al. PubChem BioAssay: 2017 update. *Nucleic Acids Res.* 45(D1), D955–D963 (2017).

21. Hu H, Bajorath J. Introducing a new category of activity cliffs combining different compound similarity criteria. *RSC Med. Chem.* 11(1), 132–141 (2020).

22. Hu H, Bajorath J. Systematic exploration of activity cliffs containing privileged substructures. *Mol. Pharmaceutics* 17(3), 979–989 (2020).

   **Systematic identification of privileged substructure-ACs.**

23. Evans BE, Rittle KE, Bock MG et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. *J. Med. Chem.* 31(12), 2235–2246 (1988).

   **Introduction of the privileged substructure concept.**

24. Muller G. Medicinal chemistry of target family-directed masterkeys. *Drug Disoc. Today* 8(15), 681–691 (2003).

25. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. *Current Opin. Chem. Biol.* 14(3), 347–361 (2010).

   **Comprehensive compendium of known privileged substructures.**

26. OEChem TK. Version 1.7.7. OpenEye Scientific Software, Inc, NM, USA (2012). www.eyesopen.com

27. Hu H, Bajorath J. New categories of activity cliffs (2020). https://doi.org/10.5281/zenodo.3660200